Neurocrine Biosciences Market Sentiment

SPY736.53+0.17%QQQ657.50+0.21%BTC/USD74,960.86−1.04%DIA512.52+0.06%GLD373.37+0.23%TLT81.85−0.09%

Premium Services

Neurocrine Biosciences Inc

NBIXNASDAQ

Trade with Public

$164.63

4.873.05%

Last update: Nov 6, 4:27 PM

Overview News Earnings Forecast Events Price Targets FinancialsSentimentOwnership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Mon Nov 2nd, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 6 days ago

Click to view the webcast

Neurocrine Biosciences Market Sentiment - Benzinga

Neurocrine Biosciences Market Sentiment

Market sentiment signals for Neurocrine Biosciences (NBIX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 8.3% short float

Options Flow▲ 0.46 P/C ratio

Insider Activity— Neutral (30d)

Analyst Consensus

Buy

25 analysts

Options Flow (P/C)

0.46

More calls — Bullish

48 calls · 22 puts

Avg Consensus PT

$202

+22.9%

Highest Price Target

$253

+53.7%

Citigroup

Lowest Price Target

$150

-8.9%

BMO Capital

Short Interest

8.3%

Rising — Bearish

Insider Activity (30d)

Neutral

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Nov 4, 2026	Guggenheim	Delma Caiati—	+36.1%	$207 → $224	Maintained	Buy
Nov 3, 2026	Piper Sandler	David Amsellem—	+30.6%	$210 → $215	Maintained	Overweight
Nov 3, 2026	Morgan Stanley	Jeffrey Hung—	+12.4%	$183 → $185	Maintained	Equal-Weight
Nov 3, 2026	RBC Capital	Brian Abrahams—	+15.4%	$187 → $190	Maintained	Outperform
Nov 3, 2026	Canaccord Genuity	Sumant Kulkarni—	+33.6%	$210 → $220	Maintained	Buy
Oct 16, 2026	Needham	Ami Fadia—	+23.9%	$204 → $204	Maintained	Buy
Oct 12, 2026	BMO Capital	Evan Seigerman—	-8.9%	$164 → $150	Maintained	Market Perform
Oct 6, 2026	Guggenheim	Delma Caiati—	+25.7%	$207	Assumes	Buy
Sep 29, 2026	UBS	Ashwani Verma—	+30.0%	$231 → $214	Maintained	Buy
Sep 11, 2026	Morgan Stanley	Jeffrey Hung—	+11.2%	$182 → $183	Maintained	Equal-Weight
Sep 8, 2026	RBC Capital	Brian Abrahams—	+20.3%	$198 → $198	Maintained	Outperform
Sep 3, 2026	Citigroup	Yigal Nochomovitz—	+53.7%	$249 → $253	Maintained	Buy
Aug 13, 2026	Morgan Stanley	Jeffrey Hung—	+10.6%	$196 → $182	Maintained	Equal-Weight
Aug 3, 2026	Canaccord Genuity	Sumant Kulkarni—	+27.6%	$200 → $210	Maintained	Buy
Aug 3, 2026	Truist Securities	Danielle Brill—	+29.4%	$200 → $213	Maintained	Buy
Aug 3, 2026	Wedbush	Laura Chico—	+17.8%	$185 → $194	Maintained	Outperform
Jul 31, 2026	Citigroup	Yigal Nochomovitz—	+51.2%	$246 → $249	Maintained	Buy
Jul 31, 2026	RBC Capital	Brian Abrahams—	+20.3%	$195 → $198	Maintained	Outperform
Jul 31, 2026	Morgan Stanley	Jeffrey Hung—	+19.1%	$193 → $196	Maintained	Equal-Weight
Jul 31, 2026	TD Cowen	Phil Nadeau—	+33.6%	$200 → $220	Maintained	Buy
Jul 31, 2026	Piper Sandler	David Amsellem—	+27.6%	$207 → $210	Maintained	Overweight
Jul 31, 2026	Cantor Fitzgerald	Josh Schimmer—	+30.6%	$210 → $215	Maintained	Overweight
Jul 31, 2026	Guggenheim	Yatin Suneja—	+34.8%	$200 → $222	Maintained	Buy
Jul 31, 2026	Stifel	Paul Matteis—	+30.6%	$188 → $215	Maintained	Buy
Jul 31, 2026	Needham	Ami Fadia—	+23.9%	$200 → $204	Maintained	Buy